Table 1 Patient characteristics.

From: Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer

Total patients (n = 110)

NonAA (n = 56)

AA (n = 54)

p-valued

Ethnicity

 Hispanic or Latino

0 (0.0%)

1 (1.9%)

0.3657

 Not Hispanic or Latino

41 (73.2%)

43 (79.6%)

 

 Unknown

15 (26.8%)

10 (18.5%)

 

Clinical variables

Age (years), median

56.0

59.5

0.795a

 Interquartile range (years)

49.0–67.3

50.8–66.0

 

Follow-up time (years), median

5.9

6.4

0.344a

 Interquartile range (years)

2.0–10.9

3.0–10.9

 

Recurrence rate, n (%)

  

0.0238b

 Yesb

8 (14.3%)

18 (33.3%)

 

 Nob

46 (82.1%)

34 (63.0%)

 

 Unknown

2 (3.6%)

2 (3.7%)

 

Adjuvant chemotherapy, n (%)

  

0.0569c

 Anthracycline + Taxanec

24 (42.9%)

18 (33.3%)

 

 Otherc

10 (17.9%)

21 (38.9%)

 

 None

9 (16.1%)

15 (27.8%)

 

 Unknown

12 (21.4%)

0 (0%)

 

Chronic conditions

Obesity (BMI > 30), n (%)

14 (25.0%)

24 (44.4%)

0.045

Hypertension, n (%)

22 (39.3%)

36 (66.7%)

0.0046

Type 2 diabetes mellitus, n (%)

5 (8.9%)

21 (38.9%)

0.0003

Autoimmunity (SLE, Sjogren’s Disease, RA, IBD, MS, Type I Diabetes Mellitus, Graves’ or Hashimoto’s Disease), n (%)

6 (10.7%)

7 (13.0%)

0.774

Chronic kidney disease, n (%)

3 (5.4%)

8 (14.8%)

0.121

Hyperlipidemia, n (%)

17 (30.4%)

17 (31.5%)

1.000

Pathological variables

Stage, n (%)

  

0.407

 I

22 (39.3%)

20 (37.0%)

 

 II

28 (50.0%)

32 (59.3%)

 

 III

6 (10.7%)

2 (3.7%)

 

Tumor size

  

0.269

 T1

29

26

 

 T2

24

24

 

 T3

1

4

 

 T4

2

0

 

Nodal status

  

0.488

 N0

33

32

 

 N1

14

18

 

 N2

4

2

 

 NA

5

2

 

Histological grade, n (%)

  

1.000

 Well-differentiated

1 (1.8%)

0 (0.0%)

 

 Moderately differentiated

10 (17.9%)

9 (16.7%)

 

 Poorly differentiated

45 (80.4%)

45 (83.3%)

 

Breast cancer biomarkers

ESR1 mRNA normalized expression, median (CI)

7.531 (7.000–7.924)

7.548 (7.287–8.435)

0.6339

ERBB2 mRNA normalized expression, median (CI)

11.13 (10.76–11.25)

11.05 (10.90–11.57)

0.8278

PGR mRNA normalized expression, median (CI)

5.661 (5.355–6.133)

6.087 (5.597–6.678)

0.6499

MKI67 mRNA normalized expression, median (CI)

13.57 (12.50–13.62)

13.57 (12.68–13.63)

0.9981

  1. ap-values determined by Mann–Whitney Test.
  2. bYes versus No only.
  3. cAnthracycline + taxanes vs. Other only.
  4. dp-values determined by Fisher’s Exact Test unless otherwise specified.
Back to article page